DNMDP

DNMDP is a small-molecule "molecular glue" that induces the complex formation between Phosphodiesterase 3A (PDE3A) and Schlafen 12 (SLFN12). While DNMDP acts as a selective inhibitor of PDE3A, its cytotoxic activity in cancer cells is independent of cAMP elevation; instead, it relies on the recruitment of SLFN12 to PDE3A, which triggers apoptosis in cells expressing both proteins. Developed through a collaboration between the Broad Institute and Bayer, DNMDP has shown efficacy in preclinical models of cervical cancer and melanoma. Due to structural liabilities, it has served as a chemical probe and a starting point for the development of more metabolically stable PDE3A-SLFN12 modulators.

Other names

6-(4-(diethylamino)-3-nitrophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one